Letter to the Editor: "Midodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial".
作者信息
Riker Richard R, Gagnon David J
机构信息
Department of Critical Care, Maine Medical Center, 22 Bramhall Street, Portland, Maine 04102, USA.
Departments of Pharmacy and Critical Care, Maine Medical Center, 22 Bramhall Street, Portland, Maine 04102, USA.
出版信息
J Crit Care. 2022 Jun;69:153995. doi: 10.1016/j.jcrc.2022.153995. Epub 2022 Feb 10.
Abstract
摘要
相似文献
1
Letter to the Editor: "Midodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial".致编辑的信：“米多君使重症监护病房患者摆脱静脉血管加压药：又一项阴性固定剂量试验”
J Crit Care. 2022 Jun;69:153995. doi: 10.1016/j.jcrc.2022.153995. Epub 2022 Feb 10.
2
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).米多君作为重症监护病房难治性低血压治疗的辅助支持：一项多中心、随机、安慰剂对照试验（MIDAS试验）。
BMC Anesthesiol. 2017 Mar 21;17(1):47. doi: 10.1186/s12871-017-0339-x.
3
LIBERATE: a study protocol for midodrine for the early liberation from vasopressor support in the intensive care unit (LIBERATE): protocol for a randomized controlled trial.LIBERATE：一项关于米多君用于重症监护病房早期脱离血管加压支持的研究方案（LIBERATE）：一项随机对照试验方案。
Trials. 2022 Mar 4;23(1):194. doi: 10.1186/s13063-022-06115-0.
4
Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.口服米多君治疗可加速 ICU 患者停止静脉血管加压素输注。
J Crit Care. 2013 Oct;28(5):756-62. doi: 10.1016/j.jcrc.2013.05.021. Epub 2013 Jul 8.
5
Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series.ICU 中美多君使用趋势：一项单中心回顾性病例系列研究。
Crit Care Med. 2018 Jul;46(7):e628-e633. doi: 10.1097/CCM.0000000000003121.
6
Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.米多君与安慰剂对重症监护病房持续性低血压患者停用血管加压药时间的影响（MIDAS）：一项国际随机临床试验。
Intensive Care Med. 2020 Oct;46(10):1884-1893. doi: 10.1007/s00134-020-06216-x. Epub 2020 Sep 3.
7
Putting midodrine on the MAP: An approach to liberation from intravenous vasopressors in vasodilatory shock.将米多君置于 MAP 之上：摆脱血管扩张性休克中静脉血管加压素的方法。
Am J Health Syst Pharm. 2022 Jun 23;79(13):1047-1055. doi: 10.1093/ajhp/zxac069.
8
Midodrine therapy for vasopressor dependent shock in the intensive care unit: a protocol for a systematic review and meta-analysis.米多君治疗重症监护病房中依赖升压药的休克：系统评价和荟萃分析的方案。
BMJ Open. 2022 Nov 23;12(11):e064060. doi: 10.1136/bmjopen-2022-064060.
9
Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting.口服米多君对治疗与颈动脉支架置入相关的低血压有效。
J Cardiovasc Pharmacol Ther. 2008 Jun;13(2):94-7. doi: 10.1177/1074248408317709.
10
Midodrine as an Adjuvant to Intravenous Vasopressor Agents in Adults With Resolving Shock: Systematic Review and Meta-Analysis.米多君作为成人休克缓解期静脉血管加压药辅助用药的系统评价和荟萃分析
J Intensive Care Med. 2020 Nov;35(11):1209-1215. doi: 10.1177/0885066619843279. Epub 2019 Apr 28.
引用本文的文献
1
Midodrine initiation criteria, dose titration, and adverse effects when administered to treat shock: A systematic review and semi-quantitative analysis.米多君用于治疗休克时的起始标准、剂量滴定及不良反应：一项系统评价与半定量分析
J Crit Care Med (Targu Mures). 2025 Jan 31;11(1):5-22. doi: 10.2478/jccm-2025-0007. eCollection 2025 Jan.
2
Midodrine use in critically ill patients: a narrative review.去氧肾上腺素在危重症患者中的应用：一项叙述性综述。
Crit Care Resusc. 2023 Oct 16;24(4):298-308. doi: 10.51893/2022.4.R. eCollection 2022 Dec 5.
本文引用的文献
1
A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study.一项米多君作为辅助血管加压药治疗重症监护患者小剂量血管加压药依赖性低血压的先导、可行性、随机对照试验：MAVERIC 研究。
J Crit Care. 2022 Feb;67:166-171. doi: 10.1016/j.jcrc.2021.11.004. Epub 2021 Nov 18.
2
Hemodynamic Effects of an Increased Midodrine Dosing Frequency.增加米多君给药频率的血流动力学效应。
Crit Care Explor. 2021 Apr 26;3(4):e0405. doi: 10.1097/CCE.0000000000000405. eCollection 2021 Apr.
3
Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study.心脏手术后使用米多君治疗持续性低血压的潜在风险：一项比较队列研究。
Ann Intensive Care. 2020 Sep 14;10(1):121. doi: 10.1186/s13613-020-00737-w.
4
Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.米多君与安慰剂对重症监护病房持续性低血压患者停用血管加压药时间的影响（MIDAS）：一项国际随机临床试验。
Intensive Care Med. 2020 Oct;46(10):1884-1893. doi: 10.1007/s00134-020-06216-x. Epub 2020 Sep 3.
5
Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series.ICU 中美多君使用趋势：一项单中心回顾性病例系列研究。
Crit Care Med. 2018 Jul;46(7):e628-e633. doi: 10.1097/CCM.0000000000003121.
6
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.米多君在脓毒性休克复苏期的可行性、实用性和安全性。
Chest. 2016 Jun;149(6):1380-3. doi: 10.1016/j.chest.2016.02.657. Epub 2016 Mar 4.
7
Midodrine for the weaning of vasopressor infusions.用于撤停血管加压药输注的米多君。
J Clin Pharm Ther. 2016 Jun;41(3):260-5. doi: 10.1111/jcpt.12375. Epub 2016 Mar 4.
8
Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.口服米多君治疗可加速 ICU 患者停止静脉血管加压素输注。
J Crit Care. 2013 Oct;28(5):756-62. doi: 10.1016/j.jcrc.2013.05.021. Epub 2013 Jul 8.
9
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.米多君治疗神经源性直立性低血压的双盲、剂量反应研究。
Neurology. 1998 Jul;51(1):120-4. doi: 10.1212/wnl.51.1.120.
Zotero 插件